CymitQuimica logo

CAS 1197953-54-0

:

Brigatinib

Description:
Brigatinib is a targeted therapy used primarily in the treatment of non-small cell lung cancer (NSCLC) that is characterized by anaplastic lymphoma kinase (ALK) gene rearrangements. It is classified as a tyrosine kinase inhibitor, specifically designed to inhibit ALK and, to a lesser extent, the epidermal growth factor receptor (EGFR). The chemical formula of Brigatinib reflects its complex structure, which includes multiple functional groups that contribute to its pharmacological activity. It is typically administered orally and has shown efficacy in patients who have developed resistance to other ALK inhibitors. The substance is known for its ability to penetrate the blood-brain barrier, making it a valuable option for treating brain metastases associated with ALK-positive NSCLC. Brigatinib's safety profile includes potential side effects such as hypertension, gastrointestinal disturbances, and pulmonary complications, necessitating careful monitoring during treatment. Overall, Brigatinib represents a significant advancement in targeted cancer therapies, offering hope for improved outcomes in specific patient populations.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 14 products.